SCHEMBL3321873

SCHEMBL3321873

COC(=O)c1c(Br)sc2c1CCC2

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.61
KDM4E B2RXH2 6/20 0.61
MAPT P10636 6/20 0.60
HPGD P15428 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MCL1 Q07820 1/20 0.56
HSD17B10 Q99714 4/20 0.55
USP2 O75604 2/20 0.55
MAPK1 P28482 2/20 0.55
TLR2 O60603 3/20 0.51
CNR2 P34972 2/20 0.50
TSHR P16473 2/20 0.50
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
POLB P06746 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19140470 0.97 ALDH1A1 (0.66) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL18499679 0.83 ALDH1A1 (0.60) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL19320697 0.81 KDM4E (0.51) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL2181401 0.80 ALDH1A1 (0.67) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL22774533 0.80 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL6999008 0.80 ALDH1A1 (0.69) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL31435555 0.80 ALDH1A1 (0.44) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL19308757 0.79 ALDH1A1 (0.65) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL18430418 0.78 ALDH1A1 (0.66) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2
SCHEMBL22774938 0.78 ALDH1A1 (0.55) ALDH1A1KDM4EMAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624023-B2 Sulfonylurea derivatives and uses thereof NodThera Limited (GB) 2026-05-12 US disclosed
EP-3983407-B1 SULFONYLUREA DERIVATIVES AND USES THEREOF NODTHERA LTD (GB) 2025-11-12 EP disclosed
CN-114222739-B Sulfonylurea derivatives and their use 诺瑟拉有限公司 2025-02-11 CN disclosed
US-20230083495-A1 SULFONYLUREA DERIVATIVES AND USES THEREOF NodThera Limited (GB) 2023-03-16 US disclosed
EP-3983407-A1 SULFONYLUREA DERIVATIVES AND USES THEREOF Nodthera Limited (GB) 2022-04-20 EP disclosed
CN-114222739-A Sulfonylurea derivatives and use thereof 诺瑟拉有限公司 2022-03-22 CN disclosed
WO-2020249664-A1 SULFONYLUREA DERIVATIVES AND USES THEREOF NodThera Limited (GB) 2020-12-17 WO disclosed
WO-2020249664-A1 SULFONYLUREA DERIVATIVES AND USES THEREOF NodThera Limited (GB) 2020-12-17 WO disclosed
US-20170253607-A1 LONG-ACTING HIV PROTEASE INHIBITOR SHIONOGI & CO., LTD. (JP) 2017-09-07 US disclosed
EP-3192794-A1 SUSTAINED HIV PROTEASE INHIBITOR Shionogi & Co., Ltd. (JP) 2017-07-19 EP disclosed
US-8367696-B2 Aza-bridged-ring compound ASTELLAS PHARMA INC. (JP) 2013-02-05 US disclosed
US-8367696-B2 Aza-bridged-ring compound ASTELLAS PHARMA INC. (JP) 2013-02-05 US disclosed
US-8367696-B2 Aza-bridged-ring compound ASTELLAS PHARMA INC. (JP) 2013-02-05 US disclosed
US-20100105658-A1 AZA-BRIDGED-RING COMPOUND ASTELLAS PHARMA INC. (JP) 2010-04-29 US disclosed
US-20100105658-A1 AZA-BRIDGED-RING COMPOUND ASTELLAS PHARMA INC. (JP) 2010-04-29 US disclosed
US-20100105658-A1 AZA-BRIDGED-RING COMPOUND ASTELLAS PHARMA INC. (JP) 2010-04-29 US disclosed
EP-2119716-A1 AZA-BRIDGED-RING COMPOUND Astellas Pharma Inc. (JP) 2009-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253607-A1 LONG-ACTING HIV PROTEASE INHIBITOR CPN1, HAT1, PRSS1 ALDH1A1 4195/4885KDM4E 1195/4885MAPT 4683/4885
US-12624023-B2 Sulfonylurea derivatives and uses thereof PYCARD, NOD1, NLRP3 ALDH1A1 561/4885KDM4E 3454/4885MAPT 4223/4885
US-20100105658-A1 AZA-BRIDGED-RING COMPOUND CHRM3, CHRM1, CHRM2 ALDH1A1 2006/4885KDM4E 1245/4885MAPT 4405/4885
US-20230083495-A1 SULFONYLUREA DERIVATIVES AND USES THEREOF IL1B, NOD1, IL1A ALDH1A1 188/4885KDM4E 3522/4885MAPT 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.